TrialNeuro-oncology2015
Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627).
Andrew B Lassman et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
105 papers cite itlatest 60 shown
this paperpooled ittrialcites it